What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Myocardial infarction
- Surgery
His primary scientific interests are in Internal medicine, Cardiology, Myocardial infarction, Surgery and Percutaneous coronary intervention.
His research in Coronary artery disease, Clopidogrel, Acute coronary syndrome, Angioplasty and Drug-eluting stent are components of Internal medicine.
His work on Management of acute coronary syndrome, Ejection fraction and Heart failure as part of general Cardiology study is frequently linked to In patient, bridging the gap between disciplines.
His work focuses on many connections between Myocardial infarction and other disciplines, such as Platelet aggregation inhibitor, that overlap with his field of interest in Pharmacotherapy, Ticlopidine and Unstable angina.
His Surgery research includes elements of Meta-analysis, TIMI and Hazard ratio.
His work in Percutaneous coronary intervention addresses issues such as Clinical trial, which are connected to fields such as Confidence interval.
His most cited work include:
- 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC) (5768 citations)
- ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation (5547 citations)
- 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). (3314 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Internal medicine, Cardiology, Percutaneous coronary intervention, Myocardial infarction and Surgery.
His study in Conventional PCI, Acute coronary syndrome, Randomized controlled trial, Coronary artery disease and Stent falls under the purview of Internal medicine.
Many of his research projects under Cardiology are closely connected to In patient with In patient, tying the diverse disciplines of science together.
His research integrates issues of Platelet aggregation inhibitor, Clopidogrel and Clinical endpoint, Clinical trial in his study of Percutaneous coronary intervention.
His studies in Myocardial infarction integrate themes in fields like Stroke and Hazard ratio, Confidence interval.
His work deals with themes such as Angioplasty, Antithrombotic, Mace and TIMI, which intersect with Surgery.
He most often published in these fields:
- Internal medicine (70.76%)
- Cardiology (56.01%)
- Percutaneous coronary intervention (47.96%)
What were the highlights of his more recent work (between 2019-2021)?
- Internal medicine (70.76%)
- Cardiology (56.01%)
- Percutaneous coronary intervention (47.96%)
In recent papers he was focusing on the following fields of study:
Marco Valgimigli spends much of his time researching Internal medicine, Cardiology, Percutaneous coronary intervention, Conventional PCI and Myocardial infarction.
His is involved in several facets of Internal medicine study, as is seen by his studies on Ticagrelor, Acute coronary syndrome, Clinical endpoint, Hazard ratio and Stroke.
His Stent research extends to the thematically linked field of Cardiology.
His Percutaneous coronary intervention study combines topics from a wide range of disciplines, such as Coronary artery disease, Regimen, Randomized controlled trial, Intensive care medicine and Aspirin.
His Conventional PCI research focuses on Framingham Risk Score and how it relates to Cohort.
His Myocardial infarction study frequently links to related topics such as Rate ratio.
Between 2019 and 2021, his most popular works were:
- 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. (1026 citations)
- 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) (424 citations)
- A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement (114 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Myocardial infarction
- Surgery
Marco Valgimigli mostly deals with Internal medicine, Percutaneous coronary intervention, Conventional PCI, Cardiology and Myocardial infarction.
His study in Ticagrelor, Acute coronary syndrome, Coronary artery disease, Stroke and Randomized controlled trial is carried out as part of his Internal medicine studies.
His biological study spans a wide range of topics, including Stent, Surrogate endpoint, Risk assessment and Renal function.
His work carried out in the field of Conventional PCI brings together such families of science as Platelet aggregation inhibitor, Framingham Risk Score, Clinical trial and Antithrombotic.
His Cardiology study frequently draws connections to adjacent fields such as Concomitant.
His work in Myocardial infarction covers topics such as Clinical endpoint which are related to areas like Target lesion.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
